Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 39-58

  Cihlar, Tomas ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

HIV reverse transcriptase; NRTI; NRTI resistance; Nucleoside; Nucleotide

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APRICITABINE; ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVUCITABINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FIALURIDINE; FOSAMPRENAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN; RIBAVIRIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CARDIOMYOPATHY; CELL CULTURE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSURIA; HEART INFARCTION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY DISEASE; LACTIC ACIDOSIS; LEUKOPENIA; LIPOATROPHY; LIVER FAILURE; LIVER TRANSPLANTATION; MYOPATHY; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PHOSPHATURIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEINURIA; REVERSE TRANSCRIPTION; REVIEW; SIDE EFFECT; TREATMENT DURATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; NUCLEOSIDES; NUCLEOTIDES; ZIDOVUDINE;

EID: 73549088038     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.09.014     Document Type: Review

References (238)

1. Agarwala S., Eley T., Villegas C., Wang Y., Hughes E., and Grasela D. Pharmacokinetic interaction between tenofovir and atazanavir coadministration with ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Abstract 16. Quebec City, Canada (2005)
2. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., and Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36 (1987) 3797-3800
3. Anderson P.L., Kakuda T.N., Kawle S., and Fletcher C.V. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17 (2003) 2159-2168
4. Arion D., Kaushik N., McCormick S., Borkow G., and Parniak M.A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37 (1998) 15908-15917
5. Arner E.S., and Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 67 (1995) 155-186
6. Arribas J.R., Pozniak A.L., Gallant J.E., Dejesus E., Gazzard B., Campo R.E., Chen S.S., McColl D., Holmes C.B., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr. 47 (2008) 74-78
7. Asif G., Hurwitz S.J., Obikhod A., Delinsky D., Narayanasamy J., Chu C.K., McClure H.M., and Schinazi R.F. Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. Antimicrob. Agents Chemother. 51 (2007) 2424-2429
8. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16 (1994) 113-126
9. Balzarini J., Cooney D.A., Dalal M., Kang G.J., Cupp J.E., DeClercq E., Broder S., and Johns D.G. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32 (1987) 798-806
10. Balzarini J., Pannecouque C., De Clercq E., Aquaro S., Perno C.F., Egberink H., and Holy A. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob. Agents Chemother. 46 (2002) 2185-2193
11. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., and Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
12. Bazmi H.Z., Hammond J.L., Cavalcanti S.C., Chu C.K., Schinazi R.F., and Mellors J.W. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44 (2000) 1783-1788
13. Becher F., Landman R., Mboup S., Kane C.N., Canestri A., Liegeois F., Vray M., Prevot M.H., Leleu G., and Benech H. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 18 (2004) 181-187
14. Bethell R.C., Lie Y.S., and Parkin N.T. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antiviral Chem. Chemother. 16 (2005) 295-302
15. Bethell R., De Muys J., Lippens J., Richard A., Hamelin B., Ren C., and Collins P. In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob. Agents Chemother. 51 (2007) 2948-2953
16. Birkus G., Hitchcock M.J., and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 716-723
17. Borst P., de Wolf C., and van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453 (2007) 661-673
18. Bottiger D., and Oberg B. Predictive value of treatment effects in SIV/SHIV infections in monkeys. Curr. Opin. Anti-Infect. Investig. Drugs 2 (2000) 255-264
19. Bourdais J., Biondi R., Sarfati S., Guerreiro C., Lascu I., Janin J., and Veron M. Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase. J. Biol. Chem. 271 (1996) 7887-7890
20. Brinkman K., ter Hofstede H.J., Burger D.M., Smeitink J.A., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12 (1998) 1735-1744
21. Broder S. The development of antiretroviral therapy and its impact on the global HIV/AIDS pandemic. Antiviral Res. 85 (2010) 1-18
22. Brothers C.H., Hernandez J.E., Cutrell A.G., Curtis L., Ait-Khaled M., Bowlin S.J., Hughes S.H., Yeo J.M., and Lapierre D.H. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J. Acquir. Immune Defic. Syndr. 51 (2009) 20-28
23. Burger D.M., Meenhorst P.L., Koks C.H., and Beijnen J.H. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother. 37 (1993) 1426-1431
24. Cahn P., Cassetti I., Wood R., Phanuphak P., Shiveley L., Bethell R.C., and Sawyer J. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20 (2006) 1261-1268
25. Cahn P., Reuss F., Rolon M., Wit F., Boehm E., and Lange J. A phase I study to explore the safety, tolerability, and pharmacokinetics of Fosalvudine Tidoxil in patients infected with HIV-1. 16th International AIDS Conference, Abstract THLB0216. Toronto, Canada (2006)
26. Cahn P., Schuermann D., Reuss F., Wit F., Boehm E., and Lange J. A phase-II study of 14 days monotherapy with the nucleoside-analogue fosalvudine tidoxil in treatment-naïve HIV-1 infected adults. 4th IAS Conference on Pathogenesis, Treatment, and Prevention, Abstract WEBEP114LB. Sydney, Australia (2007)
27. Cahn P., Sosa N., Wiznia A., Patel M., Ward D., Palella F., Sierra-Madero J., Wheeler D., DeJesus E., Otto M., and Team R.S. Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and <3 TAM. 14th Conference on Retroviruses and Opportunistic Infections, Abstract 488. Los Angeles, CA (2007)
28. Cahn P., Altclas J., Martins M., Losso M., Cassetti I., Cox S., and Cooper D.A. 48-week data from study AVX-201-a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. J. Int. AIDS Soc. 11 Suppl. 1 (2008) O41
29. Calmy A., Petoumenos K., Lewden C., Law M., Bocquentin F., Hesse K., Cooper D., Carr A., and Bonnet F. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Med. 8 (2007) 171-180
30. Carr A., Miller J., Law M., and Cooper D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14 (2000) F25-F32
31. Cass C.E., Young J.D., Baldwin S.A., Cabrita M.A., Graham K.A., Griffiths M., Jennings L.L., Mackey J.R., Ng A.M., Ritzel M.W., Vickers M.F., and Yao S.Y. Nucleoside transporters of mammalian cells. Pharm. Biotechnol. 12 (1999) 313-352
32. Cassetti I., Madruga J.V., Suleiman J.M., Etzel A., Zhong L., Cheng A.K., and Enejosa J. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials 8 (2007) 164-172
33. Chen C.H., and Cheng Y.C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′-dideoxycytidine. J. Biol. Chem. 267 (1992) 2856-2859
34. Chu C.K., Yadav V., Chong Y.H., and Schinazi R.F. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J. Med. Chem. 48 (2005) 3949-3952
35. Cihlar T., and Chen M.S. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases α, β and γ. Antiviral Chem. Chemother. 8 (1997) 187-195
36. Cihlar T., Ho E.S., Lin D.C., and Mulato A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20 (2001) 641-648
37. Cihlar T., Ray A.S., Laflamme G., Vela J.E., Tong L., Fuller M.D., Roy A., and Rhodes G.R. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antiviral Ther. 12 (2007) 267-272
38. Cihlar T., Ray A.S., Boojamra C.G., Zhang L., Hui H., Laflamme G., Vela J.E., Grant D., Chen J., Myrick F., White K.L., Gao Y., Lin K.Y., Douglas J.L., Parkin N.T., Carey A., Pakdaman R., and Mackman R.L. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob. Agents Chemother. 52 (2008) 655-665
39. Cihlar T., Laflamme G., Fisher R., Carey A.C., Vela J.E., Mackman R., and Ray A.S. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob. Agents Chemother. 53 (2009) 150-156
40. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
41. Colucci P., Pottage J., Robison H., Schrmann D., Donohue M., Gugliotti R., and Ducharme M.P. Efficacy and novel pharmacology of elvucitabine in a 7 day placebo controlled monotherapy study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract H-1670d. San Francisco, CA, USA (2006)
42. Colucci P., Pottage J.C., Robison H., Turgeon J., Schurmann D., Hoepelman I.M., and Ducharme M.P. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob. Agents Chemother. 53 (2009) 662-669
43. Cox S., and Southby J. Apricitabine-a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Exp. Opin. Investig. Drugs 18 (2009) 199-209
44. Cox S., Southby S., and Moore J. Genotypic analysis of patients enrolled in study AVX-201 and treated with apricitabine for 24 weeks. Antiviral Ther. 13 Suppl. 3 (2008) A22
45. Cretton E.M., and Sommadossi J.P. Reduction of 3′-azido-2′,3′-dideoxynucleosides to their 3′-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes. Drug Metab. Dispos. 21 (1993) 946-950
46. Cretton E.M., Zhou Z., Kidd L.B., McClure H.M., Kaul S., Hitchcock M.J., and Sommadossi J.P. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrob. Agents Chemother. 37 (1993) 1816-1825
47. Cui L., Schinazi R.F., Gosselin G., Imbach J.L., Chu C.K., Rando R.F., Revankar G.R., and Sommadossi J.P. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52 (1996) 1577-1584
48. Dalakas M.C., Illa I., Pezeshkpour G.H., Laukaitis J.P., Cohen B., and Griffin J.L. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322 (1990) 1098-1105
49. de Baar M.P., de Rooij E.R., Smolders K.G., van Schijndel H.B., Timmermans E.C., and Bethell R. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. Antiviral Res. 76 (2007) 68-74
50. De Clercq E., Andrei G., Balzarini J., Leyssen P., Naesens L., Neyts J., Pannecouque C., Snoeck R., Ying C., Hockova D., and Holy A. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 24 (2005) 331-341
51. de Muys J.M., Gourdeau H., Nguyen-Ba N., Taylor D.L., Ahmed P.S., Mansour T., Locas C., Richard N., Wainberg M.A., and Rando R.F. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob. Agents Chemother. 43 (1999) 1835-1844
52. DeJesus E.D., Saple D., Morales-Ramirez J., Kumarasamy N., Jefferson T., Bellos N., Wade B., Gugliotti R., Robinson H., and Olek E. Elvucitabine phase II 48 week interim results show safety and efficacy profiles similar to lamivudine in treatment naïve HIV-1 infected patients with a unique pharmacokinetic profile. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract H-892. Washington, DC, USA (2008)
53. Dickinson L., Khoo S., and Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. 85 (2010) 176-189
54. Dornsife R.E., and Averett D.R. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob. Agents Chemother. 40 (1996) 514-519
55. Doublie S., Tabor S., Long A.M., Richardson C.C., and Ellenberger T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 Å resolution. Nature 391 (1998) 251-258
56. Dunkle L.M., Gathe J.C., Pedevillano D.E., Robison H.G., Rice W.G., Pottage J.C., and ACH-006 Study Team. Elvucitabine: potent antiviral activity demonstrated in multidrug-resistant HIV infection. Antivir. Ther. 8 (2003) 85
57. Dutschman G.E., Bridges E.G., Liu S.H., Gullen E., Guo X., Kukhanova M., and Cheng Y.C. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42 (1998) 1799-1804
58. Dutschman G.E., Grill S.P., Gullen E.A., Haraguchi K., Takeda S., Tanaka H., Baba M., and Cheng Y.C. Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 48 (2004) 1640-1646
59. Fagard C., Descamps D., Dubar V., Colin C., Taburet A.M., Roquebert B., Katlama C., Jacomet C., Piketty C., Molina J.M., Chene G., and Yazdanpanah Y. Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial. 4th IAS Conference on Pathogenesis, Treatment, and Prevention, Abstract TUPDB204. Cape Town, South Africa (2009)
60. Faletto M.B., Miller W.H., Garvey E.P., St. Clair M.H., Daluge S.M., and Good S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41 (1997) 1099-1107
61. Faraj A., Schinazi R.F., Xie M.Y., Gosselin G., Perigaud C., Imbach J.L., and Sommadossi J.P. Selective protection of toxicity of 2′,3′-dideoxypyrimidine nucleoside analogs by beta-D-uridine in human granulocyte-macrophage progenitor cells. Antiviral Res. 29 (1996) 261-267
62. Feng J.Y., and Anderson K.S. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38 (1999) 55-63
63. Feng J.Y., Shi J., Schinazi R.F., and Anderson K.S. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 13 (1999) 1511-1517
64. Feng J.Y., Murakami E., Zorca S.M., Johnson A.A., Johnson K.A., Schinazi R.F., Furman P.A., and Anderson K.S. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. 48 (2004) 1300-1306
65. Feng J.Y., Parker W.B., Krajewski M.L., Deville-Bonne D., Veron M., Krishnan P., Cheng Y.C., and Borroto-Esoda K. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 68 (2004) 1879-1888
66. Fischl M.A., Collier A.C., Mukherjee A.L., Feinberg J.E., Demeter L.M., Tebas P., Giuliano M., Dehlinger M., Garren K., Brizz B., and Bassett R. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 21 (2007) 325-333
67. Flexner C., van der Horst C., Jacobson M.A., Powderly W., Duncanson F., Ganes D., Barditch-Crovo P.A., Petty B.G., Baron P.A., Armstrong D., et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J. Infect. Dis. 170 (1994) 1394-1403
68. Furman P.A., Fyfe J.A., St. Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8333-8337
69. Furman P.A., Jeffrey J., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., Hill E., Copeland W.C., Chu C.K., Sommadossi J.P., Liberman I., Schinazi R.F., and Painter G.R. Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob. Agents Chemother. 45 (2001) 158-165
70. Gallant J.E., Winston J.A., DeJesus E., Pozniak A.L., Chen S.S., Cheng A.K., and Enejosa J.V. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22 (2008) 2155-2163
71. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., Coakley D.F., Lu B., Toole J.J., and Cheng A.K. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
72. Gallant J.E., Rodriguez A.E., Weinberg W.G., Young B., Berger D.S., Lim M.L., Liao Q., Ross L., Johnson J., Shaefer M.S., and ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192 (2005) 1921-1930
73. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., Lu B., McColl D., Chuck S., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354 (2006) 251-260
74. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., Safai B., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984) 500-503
75. Gao W.Y., Shirasaka T., Johns D.G., Broder S., and Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91 (1993) 2326-2333
76. Garcia-Lerma J.G., Otten R.A., Qari S.H., Jackson E., Cong M.E., Masciotra S., Luo W., Kim C., Adams D.R., Monsour M., Lipscomb J., Johnson J.A., Delinsky D., Schinazi R.F., Janssen R., Folks T.M., and Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5 (2008) e28
77. Gerstoft J., Kirk O., Obel N., Pedersen C., Mathiesen L., Nielsen H., Katzenstein T.L., and Lundgren J.D. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. Aids 17 (2003) 2045-2052
78. Ghosn J., Quinson A.M., Sabo N., Cotte L., Piketty C., Dorleacq N., Bravo M.L., Mayers D., Harmenberg J., Mardh G., Valdez H., and Katlama C. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial. HIV Med. 8 (2007) 142-147
79. Gripshover B.M., Ribaudo H., Santana J., Gerber J.G., Campbell T.B., Hogg E., Jarocki B., Hammer S.M., and Kuritzkes D.R. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antiviral Ther. 11 (2006) 619-623
80. Gu Z., Wainberg M.A., Nguyen-Ba N., L′Heureux L., de Muys J.M., Bowlin T.L., and Rando R.F. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43 (1999) 2376-2382
81. Gu Z., Allard B., de Muys J.M., Lippens J., Rando R.F., Nguyen-Ba N., Ren C., McKenna P., Taylor D.L., and Bethell R.C. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50 (2006) 625-631
82. Gulick R.M., Ribaudo H.J., Shikuma C.M., Lustgarten S., Squires K.E., Meyer W.A.3r., Acosta E.P., Schackman B.R., Pilcher C.D., Murphy R.L., Maher W.E., Witt M.D., Reichman R.C., Snyder S., Klingman K.L., and Kuritzkes D.R. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350 (2004) 1850-1861
83. Guo Y., Kotova E., Chen Z.S., Lee K., Hopper-Borge E., Belinsky M.G., and Kruh G.D. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J. Biol. Chem. 278 (2003) 29509-29514
84. Hammond J.L., Parikh U.M., Koontz D.L., Schlueter-Wirtz S., Chu C.K., Bazmi H.Z., Schinazi R.F., and Mellors J.W. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. Antimicrob. Agents Chemother. 49 (2005) 3930-3932
85. Hanes J.W., and Johnson K.A. Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. 52 (2008) 253-258
86. Haraguchi K., Takeda S., Tanaka H., Nitanda T., Baba M., Dutschman G.E., and Cheng Y.C. Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg. Med. Chem. Lett. 13 (2003) 3775-3777
87. Haraguchi K., Shimada H., Tanaka H., Hamasaki T., Baba M., Gullen E.A., Dutschman G.E., and Cheng Y.C. Synthesis and anti-HIV activity of 4′-substituted 4′-thiothymidines: a new entry based on nucleophilic substitution of the 4′-acetoxy group. J. Med. Chem. 51 (2008) 1885-1893
88. Harmenberg J., Ageland H., Borg N., Bottiger D., Johansson N.G., Lofgren B., Oberg B., Pelcman N., Schroder I., Stahle L., Vrang L., Zhang H., and Zhou X. Studies of FLG as a potent and selective inhibitor of hepatitis B virus replication in vitro and in vivo. 11th International Conference on Antiviral Research, Abstract 90. San Diego, CA, USA (1998)
89. Harmenberg J., Larsson T., Bottiger D., Augustsson E., Mardh G., and Oberg B. Pharmacokinetic evaluation of the hepatitis B nucleoside analogue MIV-210 in human volunteers. 15th International Conference on Antiviral Research, Abstract 150. Prague, Czech Republic (2002)
90. Harris M., Back D., Kewn S., Jutha S., Marina R., and Montaner J.S. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 16 (2002) 1196-1197
91. Harris K.S., Brabant W., Styrchak S., Gall A., and Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 67 (2005) 1-9
92. Hartman N.R., Ahluwalia G.S., Cooney D.A., Mitsuya H., Kageyama S., Fridland A., Broder S., and Johns D.G. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol. Pharmacol. 40 (1991) 118-124
93. Hattori S., Ide K., Nakata H., Harada H., Suzu S., Ashida N., Kohgo S., Hayakawa H., Mitsuya H., and Okada S. Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against HIV-1 infection in Hu-PBMC-NOD/SCID/JAK3null (NOJ) mouse model. Antimicrob. Agents Chemother. (2009) (June 22; Epub ahead of print)
94. Haubrich R.H., Riddler S.A., DiRienzo A.G., Komarow L., Powderly W.G., Klingman K., Garren K.W., Butcher D.L., Rooney J.F., Haas D.W., Mellors J.W., and Havlir D.V. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23 (2009) 1109-1118
95. Havlir D.V., Tierney C., Friedland G.H., Pollard R.B., Smeaton L., Sommadossi J.P., Fox L., Kessler H., Fife K.H., and Richman D.D. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182 (2000) 321-325
96. Hawkins T. Understanding and managing the adverse effects of HAART. Antiviral Res. 85 (2010) 201-209
97. Hawkins T., Veikley W., St. Claire III R.L., Guyer B., Clark N., and Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39 (2005) 406-411
98. Hayakawa H., Kohgo S., Kitano K., Ashida N., Kodama E., Mitsuya H., and Ohrui H. Potential of 4′-C-substituted nucleosides for the treatment of HIV-1. Antiviral Chem. Chemother. 15 (2004) 169-187
99. Hediger M.A., Romero M.F., Peng J.B., Rolfs A., Takanaga H., and Bruford E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 447 (2004) 465-468
100. Herdewijn P., Balzarini J., Baba M., Pauwels R., Van Aerschot A., Janssen G., and De Clercq E. Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. J. Med. Chem. 31 (1988) 2040-2048
101. Herzmann C., Arasteh K., Murphy R.L., Schulbin H., Kreckel P., Drauz D., Schinazi R.F., Beard A., Cartee L., and Otto M.J. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2′,3′-dideoxy-5-fluoro-3′-thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49 (2005) 2828-2833
102. Ho H.T., and Hitchcock M.J. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33 (1989) 844-849
103. Hockova D., Holy A., Masojidkova M., Andrei G., Snoeck R., De Clercq E., and Balzarini J. 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J. Med. Chem. 46 (2003) 5064-5073
104. Hostetler K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82 (2009) A84-A98
105. Hsue P.Y., Hunt P.W., Wu Y., Schnell A., Ho J.E., Hatano H., Xie Y., Martin J.N., Ganz P., and Deeks S.G. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS (2009)
106. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
107. Hunsucker S.A., Mitchell B.S., and Spychala J. The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107 (2005) 1-30
108. Imaoka T., Kusuhara H., Adachi M., Schuetz J.D., Takeuchi K., and Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71 (2007) 619-627
109. Johansson N.G., and Eriksson S. Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim. Pol. 43 (1996) 143-160
110. Johnson M.A., and Fridland A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36 (1989) 291-295
111. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., and Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276 (2001) 40847-40857
112. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., Smith A., Bennett D.E., Monsour M., Sandstrom P., Lanier E.R., and Heneine W. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5 (2008) e158
113. Joyce C.M., and Benkovic S.J. DNA polymerase fidelity: kinetics, structure, and checkpoints. Biochemistry 43 (2004) 14317-14324
114. Karim S., and Baxter C. Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. HIV Ther. 3 (2009) 3-6
115. Kati W.M., Johnson K.A., Jerva L.F., and Anderson K.S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267 (1992) 25988-25997
116. Katlama C., Ghosn J., Tubiana R., Wirden M., Valantin M.A., Harmenberg J., Mardh G., Oberg B., and Calvez V. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 18 (2004) 1299-1304
117. Kawamoto A., Kodama E., Sarafianos S.G., Sakagami Y., Kohgo S., Kitano K., Ashida N., Iwai Y., Hayakawa H., Nakata H., Mitsuya H., Arnold E., and Matsuoka M. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell. Biol. 40 (2008) 2410-2420
118. Kepler T.B., and Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11514-11519
119. Kim C.U., Luh B.Y., and Martin J.C. Regiospecific and highly stereoselective electrophilic addition to furanoid glycals: synthesis of phosphonate nucleotide analogues with potent activity against HIV. J. Org. Chem. 56 (1991) 2642-2647
120. Kim E.Y., Vrang L., Oberg B., and Merigan T.C. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Res. Hum. Retroviruses 17 (2001) 401-407
121. Kiser J.J., Carten M.L., Aquilante C.L., Anderson P.L., Wolfe P., King T.M., Delahunty T., Bushman L.R., and Fletcher C.V. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83 (2008) 265-272
122. Klumpp K., Kalayanov G., Ma H., Le Pogam S., Leveque V., Jiang W.R., Inocencio N., De Witte A., Rajyaguru S., Tai E., Chanda S., Irwin M.R., Sund C., Winqist A., Maltseva T., Eriksson S., Usova E., Smith M., Alker A., Najera I., Cammack N., Martin J.A., Johansson N.G., and Smith D.B. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J. Biol. Chem. 283 (2008) 2167-2175
123. Klumpp K., Su G., Leveque V., Deval J., Heilek G., Rajyaguru S., Li Y., Hang J.Q., Ma H., Inocencio N., Kalayanov G., Winqist A., Smith D.B., Cammack N., Johansson N.G., and Najera I. 2′-Deoxynucleoside analogs can be potent dual inhibitors of HCV and HIV replication with selectivity against human polymerases. 22nd International Conference on Antiviral Research, Abstract 16. Miami Beach, FL, USA (2009)
124. Kong X.B., Zhu Q.Y., Vidal P.M., Watanabe K.A., Polsky B., Armstrong D., Ostrander M., Lang Jr. S.A., Muchmore E., and Chou T.C. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 36 (1992) 808-818
125. Krishnan P., Fu Q., Lam W., Liou J.Y., Dutschman G., and Cheng Y.C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 277 (2002) 5453-5459
126. Lanier E., Scott J., Ait-Khaled M., Craig C., Alcorn T., Irlbeck D., Gerondelis P., Burgess R., and Underwood M. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002. 10th Conference on Retroviruses and Opportunistic Infections, Abstract 635. Boston, MA, USA (2003)
127. Lanier, E., Scott, J., Ait-Khaled, M., Craig, C., Alcorn, T., Irlbeck, D., Gerondelis, P., Burgess, R., Underwood, M., 2003b. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002. In: 10th Conference on Retroviruses and Opportunistic Infections, Abstr. 635 Boston MA USA.
128. Lanier R., Lampert B., Robertson A., Almond M., and Painter G. Hexadecyloxypropyl tenofovir associates directly with HIV and subsequently inhibits viral replication in untreated cells. 16th Conference on retroviruses and Opportunistic Infections, Abstract 556. Montreal, Canada (2009)
129. Lanier R., Lampert B., Trosta L., Almonda M., and Painter G. Development of hexadecyloxypropyl tenofovir (CMX157) for HIV: potential for use as a microbicide and therapeutic. 22th International Conference on Antiviral Research, Abstract 89. Miami Beach, FL, USA (2009)
130. Lansdon E., Samuel D., Lagpacan L., White K., Boojamra C., Mackman R., Cihlar T., Ray A., McGrath M., and Swaminathan S. High-resolution crystallographic analysis of the competitive binding of a novel nucleotide analog GS-9148-diphosphate to HIV-1 reverse transcriptase. 16th Conference on Retroviruses and Opportunistic Infections, Abstract 66LB. Montreal, Canada (2009)
131. Lee W.A., He G.X., Eisenberg E., Cihlar T., Swaminathan S., Mulato A., and Cundy K.C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49 (2005) 1898-1906
132. Lennerstrand J., Chu C.K., and Schinazi R.F. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate. Antimicrob. Agents Chemother. 51 (2007) 2078-2084
133. Lewis W., Papoian T., Gonzalez B., Louie H., Kelly D.P., Payne R.M., and Grody W.W. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab. Invest. 65 (1991) 228-236
134. Liang Y., Narayanasamy J., Schinazi R.F., and Chu C.K. Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. Bioorg. Med. Chem. 14 (2006) 2178-2189
135. Liang Y., Sharon A., Grier J.P., Rapp K.L., Schinazi R.F., and Chu C.K. 5′-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies. Bioorg. Med. Chem. 17 (2009) 1404-1409
136. Lin T.S., Luo M.Z., Liu M.C., Zhu Y.L., Gullen E., Dutschman G.E., and Cheng Y.C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39 (1996) 1757-1759
137. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
138. Luber A., Slowinski D., Andrews M., Olson K., Peloquin C., Pakes G., Pappa K., Shelton M., and Condoluci D. Steady-state pharmacokinetics (PK) of tenofovir (TDF) and fosamprenavir (FPV) after once daily (QD) TDF with unboosted or ritonavir (R)-boosted twice daily (BID) FPV in healthy volunteers. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2006)
139. Maag H., Rydzewski R.M., McRoberts M.J., Crawford-Ruth D., Verheyden J.P., and Prisbe E.J. Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides. J. Med. Chem. 35 (1992) 1440-1451
140. Maida I., Nunez M., Rios M.J., Martin-Carbonero L., Sotgiu G., Toro C., Rivas P., Barreiro P., Mura M.S., Babudieri S., Garcia-Samaniego J., Gonzalez-Lahoz J., and Soriano V. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J. Acquir. Immune Defic. Syndr. 42 (2006) 177-182
141. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., and Christiansen F.T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
142. Marchand B., Michailidis L., Fopoussi A., Kodama E., Matsuoka M., Ashida N., Nagy E., Parniak M., Mitsuya H., and Sarafianos S. Biochemical mechanism of HIV-1 reverse transcriptase inhibition and resistance to translocation-deficient RT inhibitors. 15th Conference on Retroviruses and Opportunistic Infections, Abstract 726a. Boston, MA, USA (2008)
143. Margolis D.M., Mukherjee A.L., Fletcher C.V., Hogg E., Ogata-Arakaki D., Petersen T., Rusin D., Martinez A., and Mellors J.W. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 21 (2007) 2025-2032
144. Martin J.L., Brown C.E., Matthews-Davis N., and Reardon J.E. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38 (1994) 2743-2749
145. Martin A.M., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F.T., Purcell A.W., McCluskey J., and Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4180-4185
146. Martin A., Almeida C., Nolan D., Cameron P., James I., Purcell A., McCluskey J., and Phillips E.S.M. Abacavir stimulates Hsp70 redistribution in antigen presenting cells of patients with hypersensitivity: association with type I alcohol dehydrogenase activity. 12th Conference on Retroviruses and Opportunistic Infections, Abstract 834. Boston, MA, USA (2005)
147. Martin J., Hitchcock M.J., De Clercq E., and Prusoff W. A brief history of the first generation nucleoside HIV reverse transcriptase inhibitors. Antiviral Res. 85 (2010) 34-38
148. Mathias A., Lee M., Callebaut C., Xu L., Tsai L., Murray B., Liu H., Yale K., Warren D., and Kearney B. GS-9350: a pharmaco-enhancer without anti-HIV activity. 15th Conference on Retroviruses and Opportunistic Infections, Abstract 40. Montreal, Canada (2009)
149. McColl D.J., Chappey C., Parkin N.T., and Miller M.D. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antiviral Ther. 13 (2008) 189-197
150. McDowell J.A., Chittick G.E., Ravitch J.R., Polk R.E., Kerkering T.M., and Stein D.S. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43 (1999) 2855-2861
151. McDowell J.A., Chittick G.E., Stevens C.P., Edwards K.D., and Stein D.S. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44 (2000) 1686-1690
152. McKee E.E., Bentley A.T., Hatch M., Gingerich J., and Susan-Resiga D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc. Toxicol. 4 (2004) 155-167
153. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., Di Bisceglie A.M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C., et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333 (1995) 1099-1105
154. Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 85 (2010) 210-231
155. Mewshaw J.P., Myrick F.T., Wakefield D.A., Hooper B.J., Harris J.L., McCreedy B., and Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29 (2002) 11-20
156. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., and Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4 (1999) 35-43
157. Michalak T.I., Zhang H., Churchill N.D., Larsson T., Johansson N.G., and Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in the woodchuck model of hepatitis B. Antimicrob. Agents Chemother. (2009) (June 29; Epub ahead of print)
158. Miller M.D. K65R, TAMs and tenofovir. AIDS Rev. 6 (2004) 22-33
159. Mitsuya H., Weinhold K.J., Furman P.A., St. Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., and Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7096-7100
160. Moyle G.J., Sabin C.A., Cartledge J., Johnson M., Wilkins E., Churchill D., Hay P., Fakoya A., Murphy M., Scullard G., Leen C., and Reilly G. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20 (2006) 2043-2050
161. Mulder L.C., Harari A., and Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 5501-5506
162. Murakami E., Ray A.S., Schinazi R.F., and Anderson K.S. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 62 (2004) 57-64
163. Murakami E., Basavapathruni A., Bradley W.D., and Anderson K.S. Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res. 67 (2005) 10-17
164. Murphy R., Zala C., Ochoa C., Tharnish P., Mathew J., Fromentin E., Asif G., Hurwitz S., Kivel N., and Schinazi R. Pharmacokinetics and potent anti-HIV-1 activity of amdoxovir plus zidovudine in a randomized double-blind placebo-controlled study. 15th Conference on Retroviruses and Opportunistic Infections, Abstract 794. Boston, MA (2008)
165. Nakata H., Amano M., Koh Y., Kodama E., Yang G., Bailey C.M., Kohgo S., Hayakawa H., Matsuoka M., Anderson K.S., Cheng Y.C., and Mitsuya H. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob. Agents Chemother. 51 (2007) 2701-2708
166. Nelson M.R., Katlama C., Montaner J.S., Cooper D.A., Gazzard B., Clotet B., Lazzarin A., Schewe K., Lange J., Wyatt C., Curtis S., Chen S.S., Smith S., Bischofberger N., and Rooney J.F. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21 (2007) 1273-1281
167. Nitanda T., Wang X., Kumamoto H., Haraguchi K., Tanaka H., Cheng Y.C., and Baba M. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49 (2005) 3355-3360
168. Ntemgwa M., Wainberg M.A., Oliveira M., Moisi D., Lalonde R., Micheli V., and Brenner B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 51 (2007) 3861-3869
169. Painter G.R., Almond M.R., Trost L.C., Lampert B.M., Neyts J., De Clercq E., Korba B.E., Aldern K.A., Beadle J.R., and Hostetler K.Y. Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51 (2007) 3505-3509
170. Paintsil E., Dutschman G.E., Hu R., Grill S.P., Lam W., Baba M., Tanaka H., and Cheng Y.C. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel thymidine analog. Antimicrob. Agents Chemother. 51 (2007) 3870-3879
171. Paintsil E., Grill S.P., Dutschman G.E., and Cheng Y.C. Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture. AIDS Res. Ther. 6 (2009) 5
172. Paintsil E., Mastuda T., Ross J., Schofield J., Cheng Y.C., and Urata Y. A Single-dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of OBP-601, a novel NRTI, in healthy subjects. 16th Conference on Retroviruses and Opportunistic Infections, Abstract 568. Montreal, Canada (2009)
173. Paltiel A.D., Freedberg K.A., Scott C.A., Schackman B.R., Losina E., Wang B., Seage G.R.3r., Sloan C.E., Sax P.E., and Walensky R.P. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin. Infect. Dis. 48 (2009) 806-815
174. Pan G., Giri N., and Elmquist W.F. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos. 35 (2007) 1165-1173
175. Parikh U.M., Koontz D.L., Chu C.K., Schinazi R.F., and Mellors J.W. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49 (2005) 1139-1144
176. Phillips E., and Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol. Diagn. Ther. 13 (2009) 1-9
177. Piliero P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 37 Suppl. 1 (2004) S2-S12
178. Pruvost A., Negredo E., Benech H., Theodoro F., Puig J., Grau E., Garcia E., Molto J., Grassi J., and Clotet B. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49 (2005) 1907-1914
179. Ray A.S. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev. 7 (2005) 113-125
180. Ray A.S., and Hitchcock M.J.M. Metabolism of antiviral nucleosides and nucleotides. In: Lafemina R.L. (Ed). Antiviral Research: Strategies in Antiviral Drug Discovery (2009), ASM Press, Washington, DC
181. Ray A.S., Yang Z., Shi J., Hobbs A., Schinazi R.F., Chu C.K., and Anderson K.S. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 41 (2002) 5150-5162
182. Ray A.S., Olson L., and Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48 (2004) 1089-1095
183. Ray A.S., Cihlar T., Robinson K.L., Tong L., Vela J.E., Fuller M.D., Wieman L.M., Eisenberg E.J., and Rhodes G.R. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50 (2006) 3297-3304
184. Ray A.S., Vela J.E., Boojamra C.G., Zhang L., Hui H., Callebaut C., Stray K., Lin K.Y., Gao Y., Mackman R.L., and Cihlar T. Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob. Agents Chemother. 52 (2008) 648-654
185. Ray A.S., Wright M.R., and Rhodes G.R. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. Clin. Pharmacol. Ther. 84 660 (2008) (Author reply 661)
186. Reardon J.E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31 (1992) 4473-4479
187. Resetar A., and Spector T. Glucuronidation of 3′-azido-3′-deoxythymidine: human and rat enzyme specificity. Biochem. Pharmacol. 38 (1989) 1389-1393
188. Reuss F., Kulke M., Braspenning J., Heckl-Östreicher B., and Opitz H.G. Fosalvudine tidoxil, a novel alovudine-derived prodrug is activated and inhibits the replication of HIV-1 in human PBMC. 16th International AIDS Conference, Abstract ThPE0025. Toronto, Canada (2006)
189. Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., Clifford D.B., Marzolini C., Fletcher C.V., Tashima K.T., Kuritzkes D.R., and Acosta E.P. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42 (2006) 401-407
190. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
191. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., and Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 323 (2009) 1304-1307
192. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Lalloo U.G., Murphy R.L., Swindells S., Havlir D., and Mellors J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358 (2008) 2095-2106
193. Roberts J.D., Bebenek K., and Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science 242 (1988) 1171-1173
194. Ross L., Lim M.L., Liao Q., Wine B., Rodriguez A.E., Weinberg W., and Shaefer M. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin. Trials 8 (2007) 1-8
195. Sabin C.A., Worm S.W., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M., D′Arminio Monforte A., Friis-Moller N., Kirk O., Pradier C., Weller I., Phillips A.N., and Lundgren J.D. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008) 1417-1426
196. Sarafianos S.G., Das K., Clark Jr. A.D., Ding J., Boyer P.L., Hughes S.H., and Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10027-10032
197. Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., and Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385 (2009) 693-713
198. Sawaya M.R., Prasad R., Wilson S.H., Kraut J., and Pelletier H. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36 (1997) 11205-11215
199. Sax P.E., Gallant J.E., and Klotman P.E. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 17 (2007) 102-103
200. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.P., St. Clair M., Wilson J., Furman P.A., et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36 (1992) 2423-2431
201. Schinazi R.F., Lloyd Jr. R.M., Nguyen M.H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., and Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37 (1993) 875-881
202. Schinazi R.F., McMillan A., Lloyd R.L., Schlueter-Wirtz S., Liotta D.C., and Chu C.K. Molecular properties of HIV-1 resistant to (+)-enantiomers and racemates of oxathiolane cytosine nucleosides and their potential for the treatment of HIV and HBV infections. Antiviral Res. 34 (1997) A42
203. Schroder I., Holmgren B., Oberg M., and Lofgren B. Inhibition of human and duck hepatitis B virus by 2′,3′-dideoxy-3′-fluoroguanosine in vitro. Antiviral Res. 37 (1998) 57-66
204. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., Kumar A., and Fridland A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5 (1999) 1048-1051
205. Shaik N., Giri N., Pan G., and Elmquist W.F. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab. Dispos. 35 (2007) 2076-2085
206. Shewach D.S., Liotta D.C., and Schinazi R.F. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45 (1993) 1540-1543
207. SMART, and DAD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22 (2008) F17-F24
208. Smith R.A., Loeb L.A., and Preston B.D. Lethal mutagenesis of HIV. Virus Res. 107 (2005) 215-228
209. Smith K.Y., Patel P., Fine D., Bellos N., Sloan L., Lackey P., Kumar P.N., Sutherland-Phillips D.H., Vavro C., Yau L., Wannamaker P., and Shaefer M.S. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23 (2009) 1547-1556
210. Sommadossi J.P. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12 Suppl. 3 (1998) S1-S8
211. Soros V.B., and Greene W.C. APOBEC3G and HIV-1: strike and counterstrike. Curr. HIV/AIDS Rep. 4 (2007) 3-9
212. Stein D.S., and Moore K.H. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21 (2001) 11-34
213. Steitz T.A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 274 (1999) 17395-17398
214. Steitz T.A., Smerdon S.J., Jager J., and Joyce C.M. A unified polymerase mechanism for nonhomologous DNA and RNA polymerases. Science 266 (1994) 2022-2025
215. Stevens R.C., Blum M.R., Rousseau F.S., and Kearney B.P. Intracellular pharmacology of emtricitabine and tenofovir. Clin. Infect. Dis. 39 (2004) 877-878 (Author reply 878-879)
216. Stoeckler J.D., Cambor C., and Parks Jr. R.E. Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates. Biochemistry 19 (1980) 102-107
217. Suo Z., and Johnson K.A. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J. Biol. Chem. 273 (1998) 27250-27258
218. Thompson M.A., Kessler H.A., Eron Jr. J.J., Jacobson J.M., Adda N., Shen G., Zong J., Harris J., Moxham C., and Rousseau F.S. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 19 (2005) 1607-1615
219. Tong L., Phan T.K., Robinson K.L., Babusis D., Strab R., Bhoopathy S., Hidalgo I.J., Rhodes G.R., and Ray A.S. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51 (2007) 3498-3504
220. Vaccaro J.A., Parnell K.M., Terezakis S.A., and Anderson K.S. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP. Antimicrob. Agents Chemother. 44 (2000) 217-221
221. Van Rompay A.R., Johansson M., and Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 87 (2000) 189-198
222. Veal G.J., Barry M.G., Khoo S.H., and Back D.J. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS Res. Hum. Retroviruses 13 (1997) 481-484
223. Vela J.E., Miller M.D., Rhodes G.R., and Ray A.S. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools. Antivir. Ther. 13 (2008) 789-797
224. Venhoff A.C., Lebrecht D., Reuss F.U., Heckl-Ostreicher B., Wehr R., Walker U.A., and Venhoff N. Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob. Agents Chemother. 53 (2009) 2748-2751
225. Wainberg M.A. The impact of the M184V substitution on drug resistance and viral fitness. Exp. Rev. Anti-Infect. Ther. 2 (2004) 147-151
226. Wang L.H., Begley J., St. Claire III R.L., Harris J., Wakeford C., and Rousseau F.S. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses 20 (2004) 1173-1182
227. Wang X., Tanaka H., Baba M., and Cheng Y.C. Study of the retention of metabolites of 4′-Ed4T, a novel anti-HIV-1 thymidine analog, in cells. Antimicrob. Agents Chemother. 53 (2009) 3317-3324
228. Waters L.J., Moyle G., Bonora S., D′Avolio A., Else L., Mandalia S., Pozniak A., Nelson M., Gazzard B., Back D., and Boffito M. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antiviral Ther. 12 (2007) 825-830
229. Weber J., Weberova J., Vazquez A., Urata Y., Matsuda T., Shafer R., Arts E., and Quinones-Mateu M. Drug susceptibility profile of OBP-601, a novel NRTI, using a comprehensive panel of NRTI- or NNRTI-resistant viruses. 15th Conference on Retroviruses and Opportunistic Infections, Abstract 726b. Boston, MA (2008)
230. White A.J. Mitochondrial toxicity and HIV therapy. Sex. Transm. Infect. 77 (2001) 158-173
231. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., and Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46 (2002) 3437-3446
232. Winston A., Pozniak A., Mandalia S., Gazzard B., Pillay D., and Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. Aids 18 (2004) 949-951
233. Wu T., Froeyen M., Kempeneers V., Pannecouque C., Wang J., Busson R., De Clercq E., and Herdewijn P. Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. J. Am. Chem. Soc. 127 (2005) 5056-5065
234. Yang G., Dutschman G.E., Wang C.J., Tanaka H., Baba M., Anderson K.S., and Cheng Y.C. Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res. 73 (2007) 185-191
235. Ying C., Holy A., Hockova D., Havlas Z., De Clercq E., and Neyts J. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob. Agents Chemother. 49 (2005) 1177-1180
236. Zhang H., Oberg B., Harmenberg J., Vrang L., Zhou X., Larsson T., and Samuelsson B. Inhibition of multiple drug resistant (MRD) HIV-1 by 3′-fluoro-2′,3′-dideoxyguanosine (FLG). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract H-182. San Diego, CA, USA (2002)
237. Zhang H., Bottiger D., Haffar O., Samuelsson B., Vrang L., and Oberg B. PPI-801, a nucleoside analogue causing chain termination by penultimate incorporation into HIV DNA. 15th International Conference on Antiviral Research, Abstract LB-03. Palm Springs, CA, USA (2007)
238. Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem. J. 285 (1992) 345-365